The Gräfelfing-based biotech company ibidi GmbH received the German bAV Award in Berlin this week. With the 3rd place in the category SME, the insurance and finance industry honored ibidi’s innovative concept of company pension plans. The jury was particularly impressed by its innovation and flexibility–a result developed in a way designed to meet the needs of internationally sought-after employees. In the 10th year of its award, the German bAV Prize thus honored for the first time a pension package for the dynamics of Start-up industries.

"For us as a company with all value-creation elements at the location, it was crucial to meet our diverse employee interests. The bAV should be fair, flexible, and reliable. This has now been awarded: “What a confirmation!", said Iris Hauerwaas, the initiating HR manager. She had taken seriously the fact that the bAV is now considered by academics to be the third most important tool for staff retention in SMEs and had therefore launched an internal campaign. Skilled workers are in high demand, especially in the high-tech market. That is why the bAV "Future in Focus" has recently rounded off ibidi’s strong benefits portfolio for retaining and attracting new employees.

The award-winning concept is a creative multi-level model with a high employer contribution. This is more likely to be found in the large corporate sector. The scale is based on length of service. Even after the probationary period, a Starter Kit with a one-time contribution of €500 motivates the employee to start an individual pension plan. In the first 5 years ibidi contributes 50% to the bAV, from the 5th to the 10th year 75% and from the 10th year the company contributes 100%! The minimum contribution of 50€ elegantly replaces the low-income mode. Employees choose their investment form individually from 3 risk types: "Security" for conventional coverage, "Growth" for the managed investment or "Opportunity" for the pension fund offering individual fund selection and partial guarantee. A third freedom of choice is then offered by the drawdown at the age of 62 to 85: as an annuity, as partial capitalization, or as a complete drawdown.

In retrospect, the chosen development approach proved to be an asset of the concept. A convincing overall package for the start-up scene was missing on the market. Therefore, the founder-led company felt compelled to create what it was looking for itself. It eventually found a solid financial services provider that embraced a practical path involving management, HR leadership, and employees. "As a company, that is actively helping to extend life expectancy and quality, we are particularly concerned about quality of life and quality of work at ibidi. We provide cell analysis tools to research laboratories worldwide. That’s why we wanted to offer our strong team more than just elementary items for life’s contingencies. It should be possible to experience old age in a financially independent way," summarized Dr. Valentin Kahl, Managing Director of ibidi. The cooperative way of finding a solution resulted in an unusual way in a now award-winning bAV. In addition, it had a highly motivating effect on the team. Appreciation and employee care can also be transferred to other high-tech start-ups or companies in the start-up environment using this method.

Please watch a short movie about the ibidi bAV success story here.

About the bAV-Prize – https://www.deutscher-bav-preis.de/

Since 2013, the "German Pension Award" has been presented annually for innovative and creative pension models that are also particularly in line with corporate or HR strategy. It was initiated by the consulting firm WTW and the event manager MCC. The aim of the award is to promote occupational pension schemes as an important pillar of retirement provision for employees in Germany and to raise public awareness of them.

Über die ibidi GmbH

ibidi GmbH, located in Gräfelfing near Munich, Germany, is a leading supplier of functional cell-based assays and products for cell microscopy. The ibidi range of products offers solutions for classic cell culturing, and also complex assays (e.g., angiogenesis, chemotaxis, and wound healing). Their products help facilitate an understanding of the development of various diseases and related therapies. ibidi’s customers are working in scientific institutions, industrial pharmacology, and biotechnology. Technology development at ibidi is supported by the BMBF (Bundesministerium für Bildung und Forschung). ibidi products are sold to customers worldwide.

Firmenkontakt und Herausgeber der Meldung:

ibidi GmbH
Lochhamer Schlag 11
82166 Gräfelfing bei München
Telefon: +49 (89) 5204617-0
Telefax: +49 (89) 5204617-59
http://www.ibidi.de

Ansprechpartner:
Iris Hauerwaas
Telefon: +49 (89) 5204617-13
E-Mail: ihauerwaas@ibidi.de
Für die oben stehende Pressemitteilung ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.

counterpixel